A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry
- 20 May 2011
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 39 (8), 1460-1467
- https://doi.org/10.1124/dmd.111.039339
Abstract
Vismodegib (GDC-0449), a small-molecule Hedgehog pathway inhibitor, was well tolerated in patients with solid tumors and showed promising efficacy in advanced basal cell carcinoma in a Phase I trial. The purpose of the study presented here was to determine routes of elimination and the extent of vismodegib metabolism, including assessment and identification of metabolites in plasma, urine, and feces. Six healthy female subjects of nonchildbearing potential were enrolled; each received a single 30-ml oral suspension containing 150 mg of vismodegib with 6.5 μg of [(14)C]vismodegib to yield a radioactivity dose of approximately 37 kBq (1000 nCi). Plasma, urine, and feces samples were collected over 56 days to permit sample collection for up to 5 elimination half-lives. Nonradioactive vismodegib was measured in plasma using liquid chromatographic-tandem mass spectrometry, and total radioactivity in plasma, urine, and feces was measured using accelerator mass spectrometry. Vismodegib was slowly eliminated by a combination of metabolism and excretion of parent drug, most of which was recovered in feces. The estimated excretion of the administered dose was 86.6% on average, with 82.2 and 4.43% recovered in feces and urine, respectively. Vismodegib was predominant in plasma, with concentrations representing >98% of the total circulating drug-related components. Metabolic pathways of vismodegib in humans included oxidation, glucuronidation, and uncommon pyridine ring cleavage. We conclude that vismodegib and any associated metabolic products are mainly eliminated through feces after oral administration in healthy volunteers.Keywords
This publication has 24 references indexed in Scilit:
- Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein BindingClinical Cancer Research, 2011
- Identification, Characterization, and Implications of Species-Dependent Plasma Protein Binding for the Oral Hedgehog Pathway Inhibitor Vismodegib (GDC-0449)Journal of Medicinal Chemistry, 2011
- Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometryJournal of Chromatography B, 2010
- Basal cell carcinomas: attack of the hedgehogNature Reviews Cancer, 2008
- Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometryInvestigational New Drugs, 2007
- A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extractsJournal of Pharmaceutical and Biomedical Analysis, 2000
- Accelerator Mass Spectrometry in Pharmaceutical Research and Development A New Ultrasensitive Analytical Method for Isotope MeasurementCurrent Drug Metabolism, 2000
- Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma SyndromeCell, 1996
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Congenital Deformities in Lambs, Calves, and Goats Resulting from Maternal Ingestion ofVeratrum californicum; Hare Lip, Cleft Palate, Ataxia, and Hypoplasia of Metacarpal and Metatarsal BonesClinical Toxicology, 1972